Partnering Opportunities

Scancell is seeking a strategic alliance partner with expertise in the development of novel vaccines with whom to co-develop SCIB1 for the treatment of melanoma.

In addition, Scancell will discuss out-licensing its proprietary ImmunoBody® vaccine technology on a target by target basis to companies wishing to develop novel ImmunoBody® vaccines for both cancer and infectious disease using their own targets or epitopes.

To discuss partnering opportunities, please contact Richard Goodfellow richardgoodfellow@scancell.co.uk